Alpha 2.0
Login Register
» Authors » Tara Symonds

Tara Symonds

Explore the profile of Tara Symonds including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 72
Citations 1034
Followers 0
Related Specialties
Urology
Gynecology & Obstetrics
Reproductive Medicine
Top 10 Co-Authors
Andrew G Bushmakin
Joseph C Cappelleri
Lucy Abraham
Louise Newton
Stacie Hudgens
Gabriel Schnetzler
Stanley E Althof
Jason A Randall
Christina Guldberg
Claire Burbridge
Published In
J Sex Med
J Patient Rep Outcomes
Orphanet J Rare Dis
J Sex Marital Ther
Muscle Nerve
Affiliations
Soon will be listed here.
Recent Articles
1.
Development and refinement of the Clinical Global Impression of Improvement for Non-seizure Symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome
Scott Andrews J, Shah D, Nacson A, Symonds T, Hughes S, Asgharnejad M, et al.
J Patient Rep Outcomes . 2025 Feb; 9(1):24. PMID: 39982628
Background: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare, severe, childhood-onset developmental and epileptic encephalopathies characterized by treatment-resistant epilepsy and varying intellectual disability levels. Clinical outcome assessments (COAs) describe...
2.
The evaluation of clinical outcomes assessments and digital health technologies in clinical trials for obesity
Goetz I, Sutter C, Abraham T, Kanu C, Boye K, Symonds T
J Patient Rep Outcomes . 2025 Feb; 9(1):23. PMID: 39976863
Background: Clinical trials for obesity have traditionally focused on weight loss and resolution of comorbidities as primary outcomes. However, secondary outcomes, such as the impact of weight reduction on patient...
3.
Development of a novel patient-reported outcome measure for disseminated coccidioidomycosis (valley fever)
Harvey E, Clegg J, Bresnik M, Blatt E, Hughes S, Umanzor-Figueroa C, et al.
J Antimicrob Chemother . 2024 Dec; 80(3):657-665. PMID: 39688396
Background: Coccidioidomycosis (Valley Fever) is a dimorphic fungal infection endemic to the southwest United States, Mexico, Central and South America, which can lead to chronic debilitating illness and death. Objectives:...
4.
Comparisons and correlations of 1-month recall vs 24-hour recall in patient-reported outcomes of an exploratory, phase 2b, randomized, double-blind, placebo-controlled clinical trial of sildenafil cream, 3.6% for the treatment of female sexual...
Johnson I, Thurman A, Cornell K, Symonds T, Hatheway J, Friend D, et al.
J Sex Med . 2024 Jul; 21(9):787-792. PMID: 39059373
Background: Efficacy assessments in clinical trials of treatments for female sexual arousal disorder (FSAD) and other female sexual dysfunction (FSD) diagnoses rely on various patient-reported outcomes (PROs). Aims: We sought...
5.
Measurement properties of the Inclusion Body Myositis Functional Rating Scale
Salam S, Symonds T, Doll H, Rousell S, Randall J, Lloyd-Price L, et al.
J Neurol Neurosurg Psychiatry . 2024 Jul; 96(2):122-131. PMID: 38960586
Objectives: To evaluate the validity, reliability, responsiveness and meaningful change threshold of the Inclusion Body Myositis (IBM) Functional Rating Scale (FRS). Methods: Data from a large 20-month multicentre, randomised, double-blind,...
6.
Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma
Cleeland C, Keating K, Cuffel B, Elbi C, Siegel J, Gerlinger C, et al.
Sci Rep . 2024 Jun; 14(1):14839. PMID: 38937473
We developed a composite symptom score (CSS) representing disease-related symptom burden over time in patients with malignant pleural mesothelioma (MPM). Longitudinal data were collected from an open-label Phase IIB study...
7.
Validation of the novel Eosinophilic Esophagitis Impact Questionnaire
McCann E, Chehade M, Spergel J, Yaworsky A, Symonds T, Stokes J, et al.
J Patient Rep Outcomes . 2023 Nov; 7(1):120. PMID: 38010430
Background: Eosinophilic esophagitis (EoE) has a detrimental effect on health-related quality of life (HRQOL). The Eosinophilic Esophagitis Impact Questionnaire (EoE-IQ) is a novel patient-reported outcome (PRO) measure assessing the impact...
8.
An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021
Sams L, Slagle A, Symonds T, Antonova J, Globe D
Value Health . 2023 Sep; 26(12):1675-1680. PMID: 37748736
Objectives: We aimed to ascertain the frequency and types of Food and Drug Administration (FDA)-identified clinical outcome assessment (COA) violations in US pharmaceutical promotional materials from 2013 to 2021 by...
9.
Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
Mauch T, Chladek M, Cataland S, Chaturvedi S, Dixon B, Garlo K, et al.
J Comp Eff Res . 2023 Jul; 12(9):e230036. PMID: 37515502
Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This...
10.
Developing Angelman syndrome-specific clinician-reported and caregiver-reported measures to support holistic, patient-centered drug development
Connor-Ahmad S, Tjeertes J, Chladek M, Newton L, Symonds T, Clinch S, et al.
Orphanet J Rare Dis . 2023 Jun; 18(1):156. PMID: 37349793
Background: Angelman syndrome (AS) is a rare, heterogenous neurogenetic condition, which significantly impacts the lives of people with AS and their families. Valid and reliable measures reporting key symptoms and...